Search icon

CANGET BIOTEKPHARMA, LLC

Company claim

Is this your business?

Get access!

Company Details

Name: CANGET BIOTEKPHARMA, LLC
Jurisdiction: New York
Legal type: DOMESTIC LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 26 Apr 2012 (13 years ago)
Entity Number: 4236998
ZIP code: 14221
County: Erie
Place of Formation: New York
Address: 102 SURREY RUN, BUFFALO, NY, United States, 14221

DOS Process Agent

Name Role Address
CANGET BIOTEKPHARMA LLC DOS Process Agent 102 SURREY RUN, BUFFALO, NY, United States, 14221

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
TJ1JCE59GKX3
CAGE Code:
6REQ2
UEI Expiration Date:
2026-03-06

Business Information

Activation Date:
2025-03-10
Initial Registration Date:
2012-05-24

Central Index Key

A CIK (Central Index Key) number is a unique identifier assigned by the U.S. Securities and Exchange Commission (SEC) to companies that: Are publicly traded on U.S. stock exchanges, File reports with the SEC.

Note: Having a CIK number indicates that: The company is registered with the SEC, Files regular financial reports (like 10-K, 10-Q), Must comply with federal securities laws and regulations, Has public shareholders, Makes financial information publicly available through SEC's EDGAR database.

CIK number:
0001781984
Phone:
7168884834

Latest Filings

Form type:
D
File number:
021-343762
Filing date:
2019-07-09
File:

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
6REQ2
Status:
Obsolete
Type:
Non-Manufacturer
CAGE Update Date:
2025-03-10
SAM Expiration:
2026-03-06

Contact Information

POC:
FENGZHI LI
Corporate URL:
http://www.canget-biotek.com/

History

Start date End date Type Value
2012-04-26 2016-04-04 Address LIPPES MATHIAS WEXLER ET'AL, 665 MAIN STREET, SUITE 300, BUFFALO, NY, 14203, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
200406061470 2020-04-06 BIENNIAL STATEMENT 2020-04-01
180507006447 2018-05-07 BIENNIAL STATEMENT 2018-04-01
160404007674 2016-04-04 BIENNIAL STATEMENT 2016-04-01
140418006331 2014-04-18 BIENNIAL STATEMENT 2014-04-01
120720000375 2012-07-20 CERTIFICATE OF PUBLICATION 2012-07-20

USAspending Awards / Financial Assistance

Date:
2023-09-12
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
PERFORM NON-GLP AND GLP TOX/TK STUDIES, AND FILE A NOVEL DRUG IND WITH THE FDA FOR ADVANCED PANCREATIC CANCER PATIENT CLINICAL TRIALS - ABSTRACT/SUMMARY THE GOALS OF THIS SBIR PHASE I GRANT ARE: (1) TO USE THE CLINICALLY COMPATIBLE FL118 PRODUCT TO PERFORM THE NON- GOOD LABORATORY PRACTICE (GLP) AND GLP TOXICOLOGY (TOX) AND TOXICOKINETICS (TK) STUDIES; AND (2) TO AUTHOR AND FILE THE FL118 INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH THE FDA FOR FIRST-IN-HUMAN FL118 PHASE 1 CLINICAL TRIALS IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC). THE REASON TO USE PDAC AS FL118’S FIRST INDICATION IN CLINICAL TRIALS IS THAT (I) FL118 TARGETS THE ONCOPROTEIN DDX5 AND SHOWS HIGH EFFICACY TO ELIMINATE PDAC WITH LOW TOXICITY; (II) PDAC IS A DIFFICULT-TO-TREAT CANCER WITH A 5-YEAR SURVIVAL RATE OF ~11% AND IS = 3% IN ADVANCED PDAC PATIENTS; (III) PDAC IS EXPECTED TO BECOME THE SECOND GREATEST CAUSE OF CANCER DEATH BY 2030; AND (IV) CURRENTLY THERE IS NO EFFECTIVE TREATMENT. THEREFORE, THERE IS AN UNMET CLINICAL NEED FOR PDAC PATIENTS. WE DISCOVERED FL118 VIA HIGH THROUGHPUT SCREENING, FOLLOWED BY IN VITRO-&-IN VIVO HIT-TO-LEAD ANALYSES. FL118 IS WATER-INSOLUBLE, WHICH HAS PREVENTED ITS DEVELOPMENT. TOGETHER WITH OUR PARTNERS, WE HAVE NOW RESOLVED THE FL118 WATER-INSOLUBLE ISSUES. FL118 HAS A UNIQUE CHEMICAL STRUCTURE OF “10,11-METHYLENEDIOXY” AND POSSESSES DISTINCT MECHANISMS OF ACTION (MOA) FROM CAMPTOTHECIN (CPT) AND ITS CLINICALLY USED ANALOGUES (E.G., IRINOTECAN AND TOPOTECAN). OUR STUDIES INDICATED THAT FL118 INHIBITS MULTIPLE ONCOGENIC PROTEINS (E.G., SURVIVIN, MCL-1, XIAP, CIAP2, MDMX, C-MYC) AND KEY DNA DAMAGE REPAIR REGULATORS (E.G., ERCC6) BY DIRECTLY TARGETING THE UPSTREAM MASTER ONCOGENIC REGULATOR DDX5. UNLIKE CLINICALLY USED CPTS, FL118 IS NOT A SUBSTRATE OF MULTI-EFFLUX PROTEINS, ABCG2/BCRP AND MDR1/PGP, AND CAN BYPASS THEIR DRUG RESISTANCE. FURTHERMORE, CANCER STEM CELLS (CSC) ARE KNOWN TO PLAY A CRITICAL ROLE IN TREATMENT RESISTANCE. ACCORDINGLY, FL118 INHIBITS BOTH CSC MARKERS (ABCG2, ALDH1A1, OCT4) AND INVASIVE CSC SPREAD. FL118 HAS DEMONSTRATED THE CAPABILITY TO ELIMINATE PDAC PATIENT- DERIVED XENOGRAFT (PDX) TUMORS AND INHIBIT PDAC METASTASIS, WHILE SHOWING LOW TOXICITY IN MURINE AND CANINE ANIMAL MODELS. FL118 IS ORALLY AVAILABLE, HIGHLY STABLE CHEMICALLY, ACCUMULATES AND RESIDES IN TUMORS, AND IS RAPIDLY CLEARED FROM THE BLOODSTREAM CIRCULATION (FAVORABLE PHARMACOKINETICS - PK). CANGET, ALONG WITH ITS PARTNER ROSWELL PARK, SUCCESSFULLY HELD THE FIRST PRE-IND MEETING (NO: PIND 133477) WITH THE FDA IN 2017. FOLLOWING THE IND GUIDELINE AND THE PRE-IND OUTLINE RECOMMENDED BY THE FDA, WE HAVE COMPLETED THE MAJOR COMPONENTS OF IND-ENABLING STUDIES AND CMC (CHEMISTRY, MANUFACTURING, AND CONTROL) WORK. FL118 HAS PASSED NUMEROUS HURDLES, AND THE RESULTS OBTAINED TO DATE FROM THE IND-ENABLING STUDIES AND OTHER PRECLINICAL STUDIES STRONGLY SUPPORT FL118 FIRST-IN-HUMAN CLINICAL TRIALS WITH PDAC PATIENTS. THE SPECIFIC AIM OF THIS SBIR PHASE I PROJECT IS TO FILE THE FL118 IND WITH THE FDA AFTER PERFORMING THE NON- GLP TOX/MTD AND GLP TOX/TK STUDIES USING THE CLINICALLY COMPATIBLE FL118 PRODUCT. TEST OF FEASIBILITY: FDA ACCEPTS OUR IND APPLICATION AND ALLOWS FOR FL118 CLINICAL TRIALS TO COMMENCE. UPON COMPLETION OF THIS PROJECT, WE WILL HAVE THE FL118 IND IN PLACE FOR QUALIFYING FL118 FIRST-IN-HUMAN CLINICAL TRIALS.
Obligated Amount:
400000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-01-23
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
34387.00
Total Face Value Of Loan:
34387.00
Date:
2020-04-15
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
34300.00
Total Face Value Of Loan:
34300.00
Date:
2018-08-14
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
A NOVEL SMALL MOLECULE FL7N-1 FOR TREATING PEDIATRIC CANCER RETINOBLASTOMA
Obligated Amount:
224919.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2014-07-22
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
A SMALL MOLECULE BROAD SPECTRUM INHIBITOR OF ANTIAPOPTOTIC GENES TO TREAT CANCER
Obligated Amount:
2326369.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Paycheck Protection Program

Date Approved:
2020-04-15
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
34300
Current Approval Amount:
34300
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
34502.98
Date Approved:
2021-01-22
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
34387
Current Approval Amount:
34387
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
34559.41

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 26 Mar 2025

Sources: New York Secretary of State